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INTRODUCTION
Glaucoma is a chronic disease and a major cause of blindness, 
with the control of intraocular pressure (IOP) being the only eviden-
ce-based mode of treatment (1-3). Appropriate treatment of glaucoma 
requires an evaluation of the rate of deterioration of the disease over 
time. Without some sense of the disease deterioration rate over time 
it is difficult to determine the real benefits of treatment(1).
Treatment persistency has been defined as total time on a de-
fined therapy, involving not just patient compliance with medical 
recommendation, but also medical decisions(4,5).
The consequence in primary open-angle glaucoma (POAG) is 
that longer persistency is also associated with the number of days of 
ABSTRACT
Purpose: To determine the proportion of blindness and investigate the relation-
ships between risk factors based on clinical characteristics and development of 
blindness in patients with primary open-angle glaucoma (POAG) treated for at 
least 15 years.
Methods: A retrospective observational chart review was performed with 403 
pa tients referred to a tertiary level hospital, each with a diagnosis of primary open-
angle glaucoma, treated for at least 15 years. Blindness attributable to glaucoma was 
defined based on visual acuity and/or visual field tests. Variables considered to be 
possible risk factors for blindness were evaluated using odds ratio (OR), confidence 
interval (95% CI), and univariate and multivariate analyses.
Results: Thirty-one patients became blind [13/53 (24.5%) - unilaterally and 18/53 
(34%) - bilaterally] during the follow-up period of treatment (19.5 ± 4.6 years, range 
15-31 years). Multivariate statistics with regression analysis revealed that persis ten -
cy on initial therapy ≤6 months was significantly associated with blindness, both 
unilateral (OR: 8.4; 95% CI: 1.3-56.4) and bilateral (OR: 7.2; 95% CI: 1.3-39.6). Other 
potential factors such as race, age, gender or number of medications were not 
associated with blindness.
Conclusion: Blindness from primary open-angle glaucoma was not uncommon in 
this population of treated patients after the long follow-up period proposed. Per-
sistence rates with the first therapy, as measured by a medical decision to change, 
were low. Persistence ≤6 months was statistically associated with the development 
of unilateral and bilateral blindness from glaucoma.
Keywords: Glaucoma, open-angle/complications; Blindness/etiology; Optic disk/phy -
siopathology; Glaucoma, open-angle /therapy; Visual acuity; Risk Factors
RESUMO
Objetivos: Determinar a frequência de cegueira e investigar a relação entre os fatores 
de risco, com base nas características clínicas e no desenvolvimento da cegueira, em 
pacientes com glaucoma primário de ângulo aberto (GPAA) tratados por mais de 15 anos.
Métodos: Realizou-se a revisão dos prontuários (estudo retrospectivo, observacional) 
de 403 pacientes referidos a um hospital de nível terciário, todos com diagnóstico de 
glaucoma primário de ângulo aberto feito em 1974 ou posteriormente, e tratados por 
no mínimo 15 anos. Cegueira atribuível ao glaucoma foi definida com base na acuidade 
visual e/ou exames de campo visual. Variáveis consideradas possíveis fatores de risco 
para cegueira (uni ou bilateral) foram avaliados usando odds ratio (OR), intervalo de 
confiança (IC95%) e análises uni e multivariadas.
Resultados: Trinta e um pacientes ficaram cegos [13/53 (24,5%) - um olho cego e 
18/53 (34%) - cegueira bilateral] durante o período de seguimento (19,5 ± 4,6 anos, 
variando de 15 a 31 anos). Estatística multivariada com análise de regressão mostrou 
que persistência com a terapia inicial ≤6 meses está significantemente associada com 
cegueira, unilateral (OR: 8,4; 95% IC: 1,3-56,4) e bilateral (OR: 7,2; 95% IC: 1,3-39,6). Outros 
potenciais fatores como raça, idade, gênero ou número de medicações não estiveram 
associados com cegueira.
Conclusão: Cegueira por glaucoma primário de ângulo aberto não foi incomum na 
popu lação de pacientes tratados e seguidos por um longo período. As taxas de persistên-
cia com a terapia inicial, medidas pela decisão médica de mudar o tratamento, foram 
baixas. Persistência ≤6 meses foi estatisticamente associada com o desenvolvimento de 
cegueira uni ou bilateral por glaucoma. 
Descritores: Glaucoma de ângulo aberto/complicações; Cegueira/etiologia; Disco ópti-
co/fisiopatologia; Glaucoma de ângulo aberto/terapia; Acuidade visual; Fatores de risco
controlled IOP(4). Therefore, we must rely on studies that characterize 
the course of treated glaucoma(6-9).
Although there is available information regarding visual field in 
long-term treatment glaucoma, other parameters could be added 
in order to enhance the understanding of the disease, such as the 
losses in nerve fiber layer and the progression of optic disc abnor-
malities(4,8-10). 
The objective of the study was to investigate the deterioration 
of visual acuity and visual field, in terms of the development of legal 
blindness, and to explore the relationship between blindness due to 
glaucoma and risk factors based on initial clinical findings in POAG pa-
tients followed for at least 15 years at a tertiary level hospital in Brazil.
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METHODS
This is a retrospective comparative study based on chart review 
of 403 patients referred to the Glaucoma Service - Medical School of 
Ribeirão Preto University Hospital, in 1974 or later, 103 of them treated 
for at least 15 years. 
Of these 103 medical records, 53 charts fulfilled the inclusion 
criteria and were included in this study. Mean follow-up period of 
treatment was 19.5 ± 4.6 years (range 15-31 years).
All patients without previous ocular surgery and with an indica-
tion of glaucoma therapy were included. We excluded patients who 
had any eye surgery other than anti-glaucomatous surgery during 
follow- up, or turned suspect of having other type of glaucoma. The 
study was conducted according to the Declaration of Helsinki and 
was approved by the institutional Review Board / Ethics Committee 
(HCRP nº 2302/2006).
Subjects included in this study (n=53) had optic nerve appea-
rance and/or visual field defects consistent with POAG, and a docu-
mented IOP of more than 21 mmHg. Optic nerve criteria included a 
cup-to-disc (C/D) ratio of 0.6 or greater in the vertical dimension, or 
C/D asymmetry of 0.2 or greater, or notching or thinning of the optic 
disc rim. Other optic disc changes related to glaucoma were consi-
dered to be additional confirmation of glaucoma. 
Patients underwent kinetic perimetry using a Goldmann peri-
meter, or achromatic static automated perimetry (SAP) using either 
the Humphrey 30-2 or 24-2 full threshold programs (Humphrey-Zeiss 
Systems, Dublin, CA). Criteria for SAP abnormality required 2 of the 
following 3 criteria to be met in at least 2 consecutive visual fields(11,12): 
(1) an abnormal glaucoma hemifield test; (2) 3 contiguous non-edge 
points (allowing the 2 nasal step edge points) on a Humphrey pro-
gram 30-2 full-threshold visual field with a P value < 0.05 on the total 
deviation plot, with at least 1 point having a P value < 0.01; (3) on full-
thres hold tests, a corrected pattern standard deviation P value < 0.05.
Because of the diversity of the visual field examinations methods 
over the extended follow-up period, a generic grading system was 
used to grade all glaucomatous field defects: grade 0 - no visual field 
defect present; grade I - nasal step or localized paracentral defect; 
grade II - nasal step and paracentral defect or a single arcuate de-
fect; grade III - two arcuate scotomas or an altitudinal scotoma not 
encroaching on fixation; grade IV - advanced visual field loss with or 
without fixation loss(13). 
Patients with ocular diseases that might mislead the interpreta-
tion of visual field testing were excluded. If an event occurred during 
follow-up that precluded further information on blindness from 
glaucoma, the patient was dropped off from the analysis. In cases 
in which other causes of visual disability were present in the same 
patient, the decision was based in the primary cause of blindness on 
the basis of the data available.
Variables considered as possible risk factors for blindness were: 
age at diagnosis, race, gender, initial visual acuity, number of anti-
glaucomatous drugs in use, IOP, optic cup-to-disc ratio and visual 
field abnormalities, persistency on initial therapy, and number of 
anti-glaucomatous surgeries.
The duration of persistency of the initial treatment was defined 
as the period between the first visit and the visit when discontinua-
tion was determined by medical decision (by inclusion, exclusion, or 
substitution of anti-glaucomatous medication or indication of laser 
or surgical treatment). Changes in the frequency, commercial name 
or dosage of the same medication in use were not considered to be 
persistency failure. Persistency was analyzed considering patients 
with six months or less on initial therapy in one category, and those 
with more than six month on initial therapy in another. 
Visual acuity was categorized as follows: category I - 20/20 to 
20/30; category II - <20/30 to 20/60; category III - <20/60 to 20/200; 
category IV - <20/200 to counts fingers; category V - counts fingers 
to no light perception.
Blindness was defined as visual acuity worse than 20/200, and/
or continuous constriction of the visual field to less than 20o in all 
four quadrants with a size III4e Goldmann stimulus or the equivalent 
on automated perimetry, allowing a higher threshold level on one 
point in one quadrant, attributable to glaucoma(14) in the worst eye 
(unilateral) or in both eyes.
Based on blindness from glaucoma at the end of follow-up, three 
groups of POAG patients were compared, using all data collec ted: 
Group 1 - Patients presenting VA ≥ 20/200 in both eyes; Group 
2 - Patients presenting unilateral blindness; and Group 3 - Patients 
pre senting bilateral blindness. For comparisons purposes, only eyes 
which became blind, in group 2 and 3, or the worse eye in group 1, 
were considered.
Data are reported as mean ± standard deviation or proportions. 
Statistical analysis included odds ratios (OR), confidence intervals 
(95% CI), exact Fisher’s exact test, unpaired t test and possible risk 
factors of blindness were studied using a multivariate model of re -
gression analysis with mixed procedures (SAS - version 9, SAS Insti -
tute Inc.).
RESULTS
At the end of follow-up 41.5% of the 53 patients studied did not 
present blindness (Group 1, n=22), 24.5% presented unilateral blind-
ness (Group 2, n=13), and 34% presented bilateral blindness (Group 
3, n=18). Thirty four (64%) of 53 patients were females and 19 (36%) 
were males. The majority of patients (35/53) were white and mean 
age at initial evaluation was 53.2 ± 11.7 years.
The initial characteristics of subjects who became blind (Group 2 
and 3) or not (Group 1) are shown in table 1.
In the comparison between Groups 1 and 2, univariate analysis 
of the variables selected as possible risk factors for blindness from 
POAG revealed that persistency ≤6 months (OR: 7.0; 95% CI: 1.2-41.3 
- P=0.013) and initial IOP (OR: 1.16; 95% CI: 1.01-1.34 - P= 0.024) were 
significantly associated with the development of unilateral blindness. 
Comparing groups 1 and 3, univariate analysis showed that persis-
tency ≤6 months (OR: 5.3; 95% CI: 1.3-21.9 - P=0.025), initial worse 
visual acuity categories [IV and V] (OR: 13.3; 95% CI: 2.2-81.2 - P= 0.004) 
and number of glaucoma surgeries (OR: 1.73; 95% CI: 1.01-2.99) were 
statistically related to bilateral blindness at the end of follow-up.
Multivariate statistics with regression analysis revealed that num-
ber of glaucoma surgeries was related only to bilateral blindness (OR: 
2.07; 95% CI: 1.09-3.92), whereas persistency ≤6 months was associa-
ted with the development of unilateral (OR: 8.4; 95% CI: 1.3-56.4) and 
bilateral (OR: 7.2; 95% CI: 1.3-39.6) blindness.
DISCUSSION
Our study indicates that POAG leads to blindness in a significant 
number of individuals, even while patients are receiving therapy. After 
approximately 19 years of follow-up, 31 treated patients became 
blind either unilaterally (24.5%) or bilaterally (34%).
Comparisons with previous studies on blindness from POAG are 
difficult because of differences in methodology, follow-up, and the 
populations studied. The systems of disc and field grading used in 
this study are believed to be more appropriate, since no stereo pho -
tography of the optic nerve head was available and, as done in other 
studies(13,14) we had to consider a categorical manner to analyze diffe-
rent visual field perimeters during the follow-up period.
Even considering the differences, a similar study conducted at a 
referral hospital(15) with 183 glaucoma patients reported that the esti-
mated risk of unilateral and bilateral blindness at 15 years was 14.6% 
and 6.4%, respectively. Another community-based study(7) analyzing 
100 patients diagnosed with “classic glaucoma”, reported higher per-
centages of blindness, almost similar to our results (54% and 22% for 
unilateral and bilateral blindness, respectively). Most other treatment 
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outcome studies, reporting worsening of the disease, reflect only 
a short-term follow-up. Kim et al.,(16) have shown, in the Advanced 
Glaucoma Intervention Study (AGIS), a 30% mean worsening of the 
visual field in two years(17). Few long-term studies have shown rates 
of worsening of about 81.4% over a 20-year follow-up(14).
We failed to find a perfect explanation for the higher proportion 
of patients who became bilaterally blind. Several possible factors may 
explain this proportion, including methodological inclusion criteria, 
such as the presence of a low proportion of patients initially not blind 
in group 3, and socioeconomic conditions. Besides, patients were 
selected from a referral glaucoma practice and may have differed in 
unknown ways from other populations of patients with glaucoma. 
Furthermore, a greater severity of disease at the time of diagnosis 
could also be associated with subsequent blindness. 
Medical decisions in terms of changing an initial proposed the -
rapy tend to be guided by clinical control of disease, economic as -
pects and health care provider, intensity of adverse effects, and mar-
keting(16). Moreover, persistency with the initial treatment results in 
reducing costs for both the patient and the health care system(1,17,18). 
The multiplicity of options for glaucoma treatment and the difficulty 
in predicting the prognosis make it difficult to adopt a strategy that 
persists as desirable(19-21). University hospitals work as referral centers 
for more complex cases of POAG and therefore one would predict 
that shorter persistency would be common(22-23). 
Most of the tertiary referral centers in ophthalmology in Brazil are 
part of the public health system, with universal access, free of cost to 
the patient and manage most of the POAG cases in the country. Com-
pared to previous studies conducted at other tertiary hospitals in Bra-
zil, our data revealed patients with similar initial characteristics(22-25). 
This study has demonstrated that low persistency with the ini-
tial therapy (≤6 months) was the only significant risk factor for the 
development of both unilateral and bilateral blindness. Moreover, 
the multivariate analysis also revealed that the number of glaucoma 
surgeries was significantly related to bilateral blindness.
Although patients who experienced clinical worsening were 
more likely to discontinue the initial therapy within the first six 
months (unpublished data), it is possible that aggressive evolution 
of POAG was associated with an early change of medical decision 
about the initial prescription or vice-versa. It is also possible that pa-
tients with a more severe glaucoma onset required a greater number 
of surgeries in an attempt to control higher IOP levels.
This was a retrospective study, and the population analyzed is 
subject to several biases, other than those related to data collection 
mentioned above. Selection bias may exist in the types of patients 
who spontaneously seek or are referred to a university clinic. Most 
of the patients were treated by different ophthalmologists, and the 
results were subject to inconsistencies. Moreover, treatment profile 
could be related with persistency differences, once the number 
of topical medications available to treat POAG has increased since 
the beginning of the recruitment period. The weight of some other 
potential risk factors may also have been biased by missing data. 
Inclusion criteria could also bias the analysis due to the potential 
effect of lowering the mean age of patients at first clinic visit. In the 
present retrospective study, these weaknesses were accepted due 
to the improbability of drawing conclusions about the long-term 
follow-up of glaucoma in other circumstances.
Although the present findings indicate that the prognosis for 
pa tients diagnosed with POAG within the past 30 years may be con -
sidered disappointing as bilateral blindness from glaucoma was not 
uncommon, a further longitudinal study is needed to determine 
more accurately whether this conclusion is valid. Besides, our results 
also suggested that low persistency with the initial therapy and the 
number of glaucoma surgeries performed was the only significant 
factors associated with the development of blindness. However, in 
the clinical practice, these factors must be considered only in com-
bination with other risk factors classically accepted in the literature.
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